RSPO3 and cancer: The proteins involved in Wnt signaling are molecular targets in cancer therapy [13,212] with clinical trials for the treatment of cancer using ETC-159 and LGK974 (Porc inhibitors) [213,214], OMP-54F28 (ipafricept: soluble FZD8) [215,216], OTSA101 (anti-FZD10 antibody) [217], OMP-18R5 (vantictumab: anti-FZD1/2/5/7/8 antibody) [218], OMP-131R10 (rosmantuzumab: anti-RSPO3 antibody) [212], PRI-724 (β-catenin/CBP inhibitor) [219,220], and UC-961 (cirmtuzumab: anti-ROR1 antibody) [221,222] ongoing (Table 4).